Team

Before joining 20Med Therapeutics in 2016, Michiel was responsible for corporate and business development at Lanthio Pharma which was acquired by MorphoSys AG in 2015. Before that he was CBO at Pepscan Therapeutics and prior to thatmanaging director of OctoPlus Inc, the Boston based US subsidiary of OctoPlus NV. Michiel holds a PhD in bioorganic chemistry from the University of Virginia and a MSc from Leiden University.

Hugo has c. 30 years of senior management experience in the pharmaceutical and biotechnology industry across multiple business models and therapeutic areas, in UK, USA, France, Russia and Germany. Hugo held the role of Managing Director of Sanofi UK and served as the Chief Marketing Officer for Sanofi Pasteur (MSD). Following his career at Sanofi, he was CEO at RQ Bio. Currently, he also holds the position of Chief Commercial Officer at Imbria. Throughout his career, Hugo has occupied key global strategic roles and has played pivotal roles in commercial operations. He has led vertically integrated teams across various functions, including Drug Discovery, Clinical Development, Regulatory Affairs, Market Access, Industrial Affairs, Medical Affairs, and Commercialization.

Prior to joining 20Med Therapeutics, Jaap held leadership positions at Nanomi BV, Eyesiu Medicines BV and BBB Therapeutics. He is trained as Biologist at Wageningen University and obtained a PhD at the Amsterdam Medical Center. Jaap has a specific focus on the preclinical development, scale-up & manufacturing of complex injectable formulations with a strong background in polymer and lipid based (nano)particles for sustained release and targeted drug delivery.